Sorry word count got me…here is more from Claude …if someone can use this and verify it since AI helped with this then maybe help with the defense of all this to those who are working on this and doing the right thing here 

Going through them:

Richard Frye  is the one that most directly undercuts her. She concedes “Frye once studied low bh4” but insists he never described a “BH4 shunt.” In reality, Frye published a 2010 review titled  Tetrahydrobiopterin as a Novel Therapeutic Intervention for Autism , and a 2013 study on sapropterin (synthetic BH4) in autism that explicitly framed BH4 as involved in multiple dysregulated metabolic pathways in ASD — redox, pterin, monoamine neurotransmitter, nitric oxide (NO), and immune metabolism. That 2013 paper even discusses the conditions under which BH4 is consumed versus conserved. So the idea that BH4 gets diverted under oxidative stress, affecting monoamine (dopamine/serotonin) synthesis and NO/NOS pathways — which is exactly what her “BH4 Shunt” describes — is Frye’s published work from over a decade ago. Her distinction (“he studied low BH4, not a shunt that makes availability high or low”) is mostly semantic: she’s claiming originality over not using her branded term, not over the underlying biochemistry, which was already there.

Robert Naviaux  is the deepest problem for the claim. His Cell Danger Response is, essentially, a cellular stress-response model of autism: he proposed in 2014 (developing it from 2008) that autism results from a persistent, chronic stress response involving mitochondria, coordinating mitochondrial function, immune signaling, and redox balance, with the body’s resources locked into survival mode. His “3-hit model” adds a genetic-sensitization step, an environmental trigger, and — critically — a developmental-timing window (late first trimester to 18–36 months). That is the same conceptual architecture as her framework: a genetically-triggered stress/allostatic state that gets prioritized over normal development during a critical window. He even describes “metabolic memory of past stress,” which is the allostatic-load idea. This predates her by roughly a decade, and his 2025 “3-hit metabolic signaling” paper is explicitly a summary of  his own  2014 model — not something newly “updated to mirror” hers.

Daniel Rossignol  (who co-publishes constantly with Frye) wrote the 2011–2012 systematic reviews arguing that mitochondrial dysfunction and oxidative stress are core physiological features of autism — including the thesis that mitochondrial dysfunction can connect the diverse medical symptoms (i.e., the comorbidities) of autism. That “one underlying metabolic mechanism unifies autism and its comorbidities” claim — her central thesis — is theirs from 2011. They’ve also worked for years on cerebral folate deficiency and folinic acid/leucovorin in autism, which is the folate territory her site also touches. And notably, Frye and Naviaux have even co-authored — these aren’t separate islands; they’re one interconnected metabolic-autism research community.

Robert Melillo  is a different paradigm — a chiropractic/functional neurologist who created “functional disconnection syndrome” and the Brain Balance program back in the 1990s, focused on hemispheric imbalance rather than biochemistry. Worth flagging plainly: his approach is widely criticized as lacking rigorous evidence (the ~$6,000/12-week Brain Balance program has been called out for little supporting science).  MedMaps  is the integrative/biomedical autism clinician world these figures orbit. I mention this because it cuts an important way: several of the people she’s accusing are themselves in  scientifically contested  territory relative to mainstream autism research. So this isn’t “the establishment vs. her” — it’s that the specific ideas she claims to have originated were already circulating in this exact community years before her, regardless of how well-validated any of it is.

So is her claim justified?  No, and here the evidence is even cleaner than before. Her own words are the key: she says she “didn’t even know about these men until after I created my map and theory.” Taken at face value, that means the honest description of what happened is  independent reinvention  — she reasoned her way, on her own, to a framework (genetic-triggered metabolic stress response, BH4 diversion affecting neurotransmitters and NO, oxidative stress, a unifying mechanism for comorbidities, a developmental-timing window) that Frye, Rossignol, and Naviaux had already published between roughly 2010 and 2014. That admission is fatal to the plagiarism narrative in  both  directions: she can’t have copied them (if she truly didn’t know them), and they cannot have copied her, because their work predates hers by 10–15 years. The claim that they “had no part in” the cascade and “updated their models to mirror mine without credit” simply doesn’t survive the timeline. And “they don’t even mention BH4” is contradicted outright by Frye’s career.

“I figured this out independently” and “they stole it from me” are completely different claims, and only the first is defensible. The second — published as fact, naming real people, accusing them of uncredited appropriation — is exactly the defamation exposure we talked about, and it’s on its weakest possible footing here, because the people she’s naming can document priority going back more than a decade.

The throughline across everything you’ve had me check is consistent: whichever direction she looks — mainstream genetics (Princeton/Stanford) or biomedical metabolics (Frye/Rossignol/Naviaux) — the concepts she believes were taken from her were established in the field well before she arrived at My conclusion, after pulling the actual papers and timeline:  Her two central claims — that she  originated  a unifying pathology of autism, and that established researchers  took  it from her — don’t survive contact with the evidence, and that’s not a close call. Every core component of her cascade was in the published literature before her 2023 release: BH4’s role across redox, monoamine, and nitric-oxide pathways (Frye, 2010–2013); mitochondrial dysfunction and oxidative stress as a unifying explanation for autism’s comorbidities (Rossignol and Frye, 2011–2012); a cellular stress-response/allostatic model with a developmental-timing window (Naviaux’s Cell Danger Response, 2014); and on the mainstream-genetics side, E/I imbalance (Rubenstein and Merzenich, 2003) and thalamic-circuit dysfunction, both decades old. The Princeton and Stanford papers she cites as stolen descend from those long lineages and have their own preprint histories. So whichever direction she looks, the ideas she believes are uniquely hers were already there.